Abstracts tagged "Clinical Science"

Abstract Number: 1308 • 2019 ACR/ARP Annual Meeting
Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
Sarah Kennedy ¹, Chris Swearingen ¹, Jeyanesh Tambiah¹, Daniel Clauw ² and Philip G Conaghan ³, ¹Samumed, LLC, San Diego, ²Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Patient-reported outcomes (PROs) in knee osteoarthritis (OA) trials have been difficult to accurately measure due to heterogenous sources of pain (e.g., from comorbid conditions…
Abstract Number: 1846 • 2017 ACR/ARHP Annual Meeting
Increased CD38hiCD27+ Plasmablast Frequency in Remission Predicts Relapsing Disease in Granulomatosis with Polyangiitis Patients
Anouk von Borstel¹, Wayel H. Abdulahad², Abraham Rutgers², Judith Land², Coen A. Stegeman¹, Peter Heeringa³ and Jan-Stephan F. Sanders¹, ¹Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Patients with granulomatosis with polyangiitis (GPA) are prone to disease relapse. Changes in anti-neutrophil cytoplasmic autoantibodies (ANCA) levels can predict relapses in individual patients…
Abstract Number: 270 • 2016 ACR/ARHP Annual Meeting
Retinoic Acid-Inducible Gene-I Increased in Peripheral CD3+T Lymphocytes of Patients with Dermatomyositis
Lu Zhang¹, Qisheng Xia², Wenli Li³, Qinglin Peng⁴ and Guochun Wang¹, ¹Rheumatology, China-Japan Friendship Hospital, Beijing, China, ²Molecular Biology Labortary, China-Japan Friedship Hospital, Beijing, China, ³Rheumatology, China-Japan Friendship Hospital, Beiing, China, ⁴Rheuamtology, China-Japan Friendship Hospital, Beijing, China
Background/Purpose: The study population included 26 treatment-naive DM patients from Department of Rheumatology at China-Japan Friendship Hospital between July 2015 and February 2016 who fulfilled…
Abstract Number: 1575 • 2015 ACR/ARHP Annual Meeting
Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Levels Are Associated with Vascular Dysfunction and Increased Cardiovascular Risk in an Animal Model and Patients with Rheumatoid Arthritis
Ruth Davies¹, Daniela Iacono², Lauren A. Jordan¹, Jessica O Williams¹, Charlotte Rawlings¹, Derek Lang³, Anwen S. Williams¹ and Ernest H. Choy¹, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²Department of Clinical and Experimental Medicine. Rheumatology Section. Second University of Naples, Naples, Italy, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in Rheumatoid arthritis (RA) patients mainly due to cardiovascular (CV) disease; however the biologic mechanisms are unknown. Increased CV risk in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].